JP2011523052A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523052A5
JP2011523052A5 JP2011510592A JP2011510592A JP2011523052A5 JP 2011523052 A5 JP2011523052 A5 JP 2011523052A5 JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011523052 A5 JP2011523052 A5 JP 2011523052A5
Authority
JP
Japan
Prior art keywords
lys
exendin
glp
aeea
mpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523052A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044135 external-priority patent/WO2009143014A1/en
Publication of JP2011523052A publication Critical patent/JP2011523052A/ja
Publication of JP2011523052A5 publication Critical patent/JP2011523052A5/ja
Pending legal-status Critical Current

Links

JP2011510592A 2008-05-23 2009-05-15 Glp−1受容体アゴニスト・バイオアッセイ Pending JP2011523052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5584208P 2008-05-23 2008-05-23
US61/055,842 2008-05-23
PCT/US2009/044135 WO2009143014A1 (en) 2008-05-23 2009-05-15 Glp-1 receptor agonist bioassays

Publications (2)

Publication Number Publication Date
JP2011523052A JP2011523052A (ja) 2011-08-04
JP2011523052A5 true JP2011523052A5 (cg-RX-API-DMAC7.html) 2012-06-28

Family

ID=41202523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510592A Pending JP2011523052A (ja) 2008-05-23 2009-05-15 Glp−1受容体アゴニスト・バイオアッセイ

Country Status (4)

Country Link
US (2) US8329419B2 (cg-RX-API-DMAC7.html)
EP (1) EP2288918A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011523052A (cg-RX-API-DMAC7.html)
WO (1) WO2009143014A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20120048003A1 (en) * 2010-08-24 2012-03-01 GOLDEN PRODUCTS LLC, Limited Liability Company Vitamin assay methods
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US20130183696A1 (en) * 2010-09-15 2013-07-18 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN103424496B (zh) * 2012-05-24 2015-02-18 山东绿叶制药有限公司 一种测定痕量艾塞那肽的方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
EP3517122A1 (en) 2013-04-03 2019-07-31 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白,及其制备方法和用途
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104569419B (zh) * 2014-09-23 2016-07-06 范列英 一种检测人血液glp-1总含量的化学发光免疫分析法试剂盒
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN109475568B (zh) 2016-05-06 2026-07-17 Ionis制药公司 Glp-1受体配体部分缀合的寡核苷酸及其用途
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
KR20230125802A (ko) * 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
FR2810406B1 (fr) 2000-06-15 2002-09-20 Cis Bio Int Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US20100009907A1 (en) * 2006-07-06 2010-01-14 Amylin Pharmaceuticals, Inc. Glucagon-Like Peptides and Uses Thereof

Similar Documents

Publication Publication Date Title
US8329419B2 (en) GLP-1 receptor agonist bioassays
AU2014236949B2 (en) Activation of bioluminescence by structural complementation
Dubois et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum
US10048280B2 (en) Immunoassay for the detection of procalcitonin
CN102187223B (zh) 检测膜蛋白内化的方法
JP6371703B2 (ja) 抗体のグリコシル化の測定方法
CN1759319A (zh) 生物液中肾上腺髓质素原中间区域部分肽的诊断检测,和实施这样的检测的免疫检测方法
CN102449147B (zh) 蛋白质间相互作用的高灵敏度检测方法
HRP20201779T1 (hr) Stanični test za otkrivanje anti-cd3 homodimera
CN104072606A (zh) 利用g蛋白偶联受体和相关组合物的筛选方法
CN1918473A (zh) 出于医学诊断目的而测定内皮素形成的方法,以及用于实施所述方法的抗体和试剂盒
JPWO2012121261A1 (ja) Oatp1b1の輸送活性を促進又は阻害する化合物をスクリーニングするための方法、及びoatp1b1発現量を測定するための方法
DK2856161T3 (en) ASSAYS
Lin et al. A time-resolved fluoroimmunoassay for the quantitation of rabies virus nucleoprotein in the rabies vaccine
KR101492167B1 (ko) 페리틴 단백질을 함유하는 표적-특이적 프로브 및 이를 이용한 바이오마커의 탐지
JPWO2013027823A1 (ja) グルカゴン様ペプチド−1の測定方法及びそれに使用するキット
CN107208315A (zh) 涉及嵌入异源蛋白质支架中的功能性多肽的方法和组合物
EP2904398B1 (en) A method for predicting the risk of getting cancer in a female subject
Orcel et al. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane
CN112739719B (zh) 结合G蛋白α的单域抗体
EP2943792B1 (en) A method for predicting the risk of getting cancer or diagnosing cancer in a subject
CN1178062C (zh) 具有确定引入的标志基团和半抗原的低聚载体分子
Mano et al. Development of nanoluciferase-based sensing system that can specifically detect 1α, 25-dihydroxyvitamin D in living cells
US20210072155A1 (en) Methods for quantifying ligand efficacy in g-protein coupled receptors using single-molecule fluorescence energy transfer
EP2828659B1 (fr) Procede de determination de la capacite d'un anticorps a maintenir des cellules a proximite l'une de l'autre